Abstract: Prostate cancer (PCa) is the most common type of cancer in men worldwide. It is a cancer that starts in the small walnut-shaped male gland called the prostate. From the prostate, it can form ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

In patients with meibomian gland dysfunction, manual digital meibomian gland compression demonstrates superior efficacy compared with mechanical compression. Manual digital meibomian gland compression ...

Prostate cancer has long been considered “immune-cold” due to the paucity of tumor-infiltrating lymphocytes and a limited response to immunotherapy. However, traditional immune checkpoint inhibitors ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive ...

1Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania. 2Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, ...

Monoamine oxidase A (MAOA) is best known for its role in neurotransmitter regulation and as the target for MAO inhibitors used as first-generation antidepressants. MAOA expression is associated with ...

Let’s be honest for a minute: talking about the prostate isn’t exactly a conversation you have over dinner, but this golf-ball-sized gland deserves WAY more attention than it gets, especially when it ...

Prostate cancer typically relies on male hormones for growth; however, prolonged hormone therapy can lead to a more aggressive form known as neuroendocrine prostate cancer (NEPC), which is resistant ...

CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel. This is an ASCO Meeting ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VCYT--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading ...